1
Dey Kaka, Gao Donghong Amy, Goldberg Daniel R, Heim Riether Alexander, Mangette John E, Mugge Ingo Andreas, Snow Roger, Swinamer Alan David, Wu Jiang Ping, Xiong Zhaoming, Yang Yu: Ccr10 antagonists. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Dey Kaka, Gao Donghong Amy, Goldberg Daniel R, Heim Riether Alexander, Mangette John E, Mugge Ingo Andreas, Snow Roger, Swinamer Alan David, Wu Jiang Ping, Xiong Zhaoming, Yang Yu, MORRIS Michael P, April 23, 2009: WO/2009/052078 (21 worldwide citation)

The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various di ...


2
Disalvo Darren, Kuzmich Daniel, Mao Can, Razavi Hossein, Sarko Christopher, Swinamer Alan David, Thomson David, Zhang Qiang: Indazole compounds as ccr1 receptor antagonists. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Disalvo Darren, Kuzmich Daniel, Mao Can, Razavi Hossein, Sarko Christopher, Swinamer Alan David, Thomson David, Zhang Qiang, MORRIS Michael P, November 5, 2009: WO/2009/134666 (13 worldwide citation)

Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disc ...


3
Cook Brian Nicholas, Harcken Christian, Lee Thomas Wai Ho, Liu Pingrong, Mao Can, Lord John, Mao Wang, Raudenbush Brian Christopher, Razavi Hossein, Sarko Christopher Ronald, Swinamer Alan David: Pyrazole compounds as ccr1 antagonists. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Cook Brian Nicholas, Harcken Christian, Lee Thomas Wai Ho, Liu Pingrong, Mao Can, Lord John, Mao Wang, Raudenbush Brian Christopher, Razavi Hossein, Sarko Christopher Ronald, Swinamer Alan David, MORRIS Michael P, November 12, 2009: WO/2009/137338 (13 worldwide citation)

Disclosed are compounds of the formula I which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple scler ...


4
Cogan Derek, Hao Ming Hong, Kamhi Victor Marc, Miller Craig Andrew, Netherton Matthew Russell, Swinamer Alan David: 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases. Boehringer Ingelheim Pharmaceuticals, Cogan Derek, Hao Ming Hong, Kamhi Victor Marc, Miller Craig Andrew, Netherton Matthew Russell, Swinamer Alan David, MORRIS Michael P, September 29, 2005: WO/2005/090333 (8 worldwide citation)

Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds a ...


5
Cogan Derek, Hao Ming Hong, Aungst Ronald A, Swinamer Alan David: Anti-cytokine heterocyclic compounds. Boehringer Ingelheim Pharmaceuticals, Cogan Derek, Hao Ming Hong, Aungst Ronald A, Swinamer Alan David, MORRIS Michael P, December 8, 2005: WO/2005/115991 (7 worldwide citation)

Disclosed are compunds of formula (I). The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these ...


6

7

8

9
Cogan Derek, Hao Ming Hong, Kahmi Victor, Miller Craig Andrew, Netherton Matthew Russell, Swinamer Alan David: 3-[4-heterocyclyl -1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases. Boehringer Ingelheim Pharma, February 13, 2008: EP1887003-A1

Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds an ...


10